Overview

A Study of MK-8189 in Participants With Schizophrenia (MK-8189-014)

Status:
Not yet recruiting
Trial end date:
2022-09-16
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to assess the safety and tolerability of multiple ascending doses of MK-8189 in participants with schizophrenia.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme LLC